Cargando…
Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients
Efficacy of early treatment with anti‐SARS‐CoV‐2 spike protein monoclonal antibodies (mAbs) for nosocomial SARS‐CoV‐2 infection in hematologic patients is unknown. Retrospective, cohort study conducted in four Italian teaching hospitals. We included adult patients with hematologic malignancies and h...
Autores principales: | Bussini, Linda, Testi, Diletta, Tazza, Beatrice, Oltolini, Chiara, Mastaglio, Sara, Sepulcri, Chiara, Campoli, Caterina, Trapani, Filippo, Pasquini, Zeno, Zappulo, Emanuela, Bassetti, Matteo, Viale, Pierluigi, Mikulska, Malgorzata, Bartoletti, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537893/ https://www.ncbi.nlm.nih.gov/pubmed/36248618 http://dx.doi.org/10.1002/jha2.554 |
Ejemplares similares
-
A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL)
por: Narkhede, Mayur, et al.
Publicado: (2023) -
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
por: Spriano, Filippo, et al.
Publicado: (2022) -
Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020) -
Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020) -
Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)